Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications
Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity. The focus of the scientific community should be on developing sensitive diagnostics that can predict immunogenicity-medi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2016/1298473 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850161739052613632 |
|---|---|
| author | Anshu Kuriakose Narendra Chirmule Pradip Nair |
| author_facet | Anshu Kuriakose Narendra Chirmule Pradip Nair |
| author_sort | Anshu Kuriakose |
| collection | DOAJ |
| description | Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity. The focus of the scientific community should be on developing sensitive diagnostics that can predict immunogenicity-mediated adverse events in the small fraction of subjects that develop clinically relevant anti-drug antibodies. Here, we discuss the causes of immunogenicity which could be product-related (inherent property of the product or might be picked up during the manufacturing process), patient-related (genetic profile or eating habits), or linked to the route of administration. We describe various posttranslational modifications (PTMs) and how they may influence immunogenicity. Over the last three decades, we have significantly improved our understanding about the types of PTMs of biotherapeutic proteins and their association with immunogenicity. It is also now clear that all PTMs do not lead to clinical immunogenicity. We also discuss the mechanisms of immunogenicity (which include T cell-dependent and T cell-independent responses) and immunological tolerance. We further elaborate on the management of immunogenicity in preclinical and clinical setting and the unique challenges raised by biosimilars, which may have different immunogenic potential from their parent biotherapeutics. |
| format | Article |
| id | doaj-art-fa477a670a0d49609930b7943b8a8e08 |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-fa477a670a0d49609930b7943b8a8e082025-08-20T02:22:44ZengWileyJournal of Immunology Research2314-88612314-71562016-01-01201610.1155/2016/12984731298473Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational ModificationsAnshu Kuriakose0Narendra Chirmule1Pradip Nair2Biocon Research Limited, Research & Development, Bangalore, Karnataka 560099, IndiaBiocon Research Limited, Research & Development, Bangalore, Karnataka 560099, IndiaBiocon Research Limited, Research & Development, Bangalore, Karnataka 560099, IndiaToday, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity. The focus of the scientific community should be on developing sensitive diagnostics that can predict immunogenicity-mediated adverse events in the small fraction of subjects that develop clinically relevant anti-drug antibodies. Here, we discuss the causes of immunogenicity which could be product-related (inherent property of the product or might be picked up during the manufacturing process), patient-related (genetic profile or eating habits), or linked to the route of administration. We describe various posttranslational modifications (PTMs) and how they may influence immunogenicity. Over the last three decades, we have significantly improved our understanding about the types of PTMs of biotherapeutic proteins and their association with immunogenicity. It is also now clear that all PTMs do not lead to clinical immunogenicity. We also discuss the mechanisms of immunogenicity (which include T cell-dependent and T cell-independent responses) and immunological tolerance. We further elaborate on the management of immunogenicity in preclinical and clinical setting and the unique challenges raised by biosimilars, which may have different immunogenic potential from their parent biotherapeutics.http://dx.doi.org/10.1155/2016/1298473 |
| spellingShingle | Anshu Kuriakose Narendra Chirmule Pradip Nair Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications Journal of Immunology Research |
| title | Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications |
| title_full | Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications |
| title_fullStr | Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications |
| title_full_unstemmed | Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications |
| title_short | Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications |
| title_sort | immunogenicity of biotherapeutics causes and association with posttranslational modifications |
| url | http://dx.doi.org/10.1155/2016/1298473 |
| work_keys_str_mv | AT anshukuriakose immunogenicityofbiotherapeuticscausesandassociationwithposttranslationalmodifications AT narendrachirmule immunogenicityofbiotherapeuticscausesandassociationwithposttranslationalmodifications AT pradipnair immunogenicityofbiotherapeuticscausesandassociationwithposttranslationalmodifications |